TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15766337
Drug: Adjusted dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted dose regimen of diamorphine 0.4 mg in hyperbaric bupivacaine 0.5%
Study: 12527943
Drug: BB-10010 with
Normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BB-10010 with dose-intensified BEMOP/CA chemotherapy
Study: 11029510
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (letrozole, anastrozole, exemestane)
Study: 9165692
Drug: BY841 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BY841 (50 mg or 100 mg twice daily)
Study: 9165692
Drug: Omeprazole (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (standard dose)
Study: 10148879
Drug: Patient-controlled administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled administration of fentanyl (n=37)
Study: 10148879
Drug: Nurse administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse administration on demand (n=43)
Study: 22444188
Drug: μ-opioid agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: μ-opioid agonist alfentanil
Study: 17209211
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation at 4 mg/d for high-risk women and 0.4 mg/d for others
Study: 12182055
Drug: L-thyroxine suppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine suppressive therapy
Study: 9408856
Drug: Mizolastine (tablet)
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (tablet)
Study: 9408856
Drug: Mizolastine (capsule)
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (capsule)
Study: 9408856
Drug: Mizolastine (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizolastine (intravenous infusion)
Study: 28081304
Drug: ACpT (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACpT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of paclitaxel 175 mg/m2)
Study: 28081304
Drug: ACdT (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACdT (4 cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 followed by 4 cycles of docetaxel 75 mg/m2)
Study: 25458980
Drug: Higher-flow nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-flow nasal cannula oxygen at 15 L/minute
Study: 25458980
Drug: Lower-flow nasal
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-flow nasal cannula oxygen at 6 L/minute
Study: 9579448
Drug: Oral tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tamoxifen 20 mg/day
Study: 21899210
Drug: Betamethasone i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone i.m. (BSP 2 mg and BDP 5 mg)
Study: 29932416
Drug: Bretol® patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretol® patch (test drug)
Study: 29932416
Drug: Hokunalin® patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hokunalin® patch (reference drug)
Study: 9131723
Drug: Clozapine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (up to 450 mg)
Study: 9131723
Drug: Zotepine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zotepine (up to 450 mg)
Study: 7703598
Drug: Glucose (1
Normalized name: Fludeoxyglucose (18F)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (1 g/kg body wt)
Study: 7703598
Drug: Fructose (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructose (1 g/kg body wt)
Study: 26494450
Drug: Sapropterin (BH4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapropterin (BH4, a nitric oxide synthase cofactor; 10 mg/kg)
Study: 21302035
Drug: HTUPA 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTUPA 10 mg
Study: 21302035
Drug: HTUPA 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTUPA 20 mg
Study: 21302035
Drug: HTUPA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTUPA 30 mg
Study: 15335019
Drug: Complex dietary
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex dietary therapy including soy isoflavones and selenium
Study: 10930895
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin for 5 days, followed by subcutaneous heparin for 5 weeks (n=8)
Study: 10930895
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous hydrocortisone for 5 days followed by oral prednisolone 40 mg daily, reducing by 5 mg per day each week (n=12)
Study: 9780100
Drug: Adjunctive daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive daunorubicin perfusion during standardized surgery
Study: 7530621
Drug: Conventional Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional Insulin Therapy (CIT; n = 12)
Study: 7530621
Drug: Continuous Subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Subcutaneous Insulin Infusion (CSII; n = 12)
Study: 7530621
Drug: Intraportal Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraportal Insulin Infusion (IPII; n = 12)
Study: 7530621
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy (CSII)
Study: 7530621
Drug: Intensified insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensified insulin therapy (IPII)
Study: 29633812
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.2% at 8 mL/h (Control)
Study: 29633812
Drug: Ropivacaine 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.4% at 4 mL/h
Study: 25287553
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy (10-14 sessions: 6-10 during pregnancy and 4-8 after delivery)
Study: 12765983
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (dalteparin) or an invasive strategy
Study: 14555594
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 microg once-daily
Study: 14555594
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 or 200 microg once-daily
Study: 14555594
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) twice-daily (100, 200, or 500 microg)
Study: 1352011
Drug: Chlorhexidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine (60 ml chlorhexidine diacetate 2 g/l)
Study: 31028503
Drug: Critical group
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical group (Routine treatment)
Study: 26265641
Drug: Three intravitreal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three intravitreal injections of bevacizumab (IVB) at monthly intervals.
Study: 22117981
Drug: Prophylactic palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic palonosetron 0.075 mg, intravenously before induction of inhalation anaesthesia
Study: 22117981
Drug: TIVA using
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIVA using propofol (target blood concentration 2.5‐6.0 μg/ml) and remifentanil (target blood concentration 2.5‐6.0 ng/ml)
Study: 19497624
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen replacement therapy (ERT)
Study: 11099873
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen replacement therapy (ERT)
Study: 17279193
Drug: Smaller multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smaller multivitamin tablets
Study: 17279193
Drug: Multivitamin tablets
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multivitamin tablets with less iron content
Study: 17279193
Drug: Standard multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multivitamin tablets (larger size, higher iron content)
Study: 7969611
Drug: Intensive care
Normalized name: Rapifen Intensive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive care treatment for more than 30 days
Study: 28860166
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg ×3/day)
Study: 20621454
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine supplementation
Study: 20621454
Drug: Olanzapine long-acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine long-acting injection (olanzapine-LAI)
Study: 16774958
Drug: Verteporfin enhanced
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin enhanced feeder vessel therapy with varying light doses (50 J/cm2, 100 J/cm2, 125 J/cm2, 150 J/cm2)
Study: 10886051
Drug: Fedotozine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fedotozine (30 mg, t.d.s.)
Study: 30001944
Drug: 900 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 μg of salbutamol
Study: 28557652
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) + Metformin (MET)
Study: 28557652
Drug: Letrozole (LE)
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole (LE) + Metformin (MET)
Study: 23893190
Drug: Sublingual specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual specific immunotherapy (SLIT) for three years
Study: 23893190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (never treated with specific immunotherapy, only symptomatic drugs)
Study: 18371963
Drug: Endometrin 100
Normalized name: Endometrin 100mg Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin 100 mg twice daily
Study: 18371963
Drug: Endometrin 100
Normalized name: Endometrin 100mg Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin 100 mg three times daily
Study: 18371963
Drug: P(4) 90
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: P(4) 90 mg 8% gel daily
Study: 11151744
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg orally twice daily for 3 days)
Study: 11151744
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched placebo orally twice daily for 3 days)
Study: 8314160
Drug: Epidoxorubicin, 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin, 30 mg/m2 (P-E)
Study: 8314160
Drug: Idarubicin, 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarubicin, 6 mg/m2 (P-I)
Study: 26921360
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin 3 mg/m2
Study: 26921360
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin 6 mg/m2
Study: 22203366
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of GABA
Study: 20185343
Drug: Intra-articular sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sodium hyaluronate (SH) injections (5 injections at weekly intervals)
Study: 20185343
Drug: Physiologic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic saline solution injections (5 injections at weekly intervals)
Study: 10606280
Drug: Cyclophosphamide, estramustine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, estramustine, or no therapy for 2 years (in NPCP 900/1000 trial)
Study: 6337742
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg orally every 6 hours for 12 weeks)
Study: 6337742
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (chronic therapy)
Study: 24444414
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (omeprazole 20 mg od)
Study: 24444414
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy (omeprazole 20 mg on-demand)
Study: 24444414
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (omeprazole 20 mg od) in NERD
Study: 24444414
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy (omeprazole 20 mg on-demand) in NERD
Study: 24444414
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (omeprazole 20 mg od) in RE
Study: 24444414
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy (omeprazole 20 mg on-demand) in RE
Study: 22943930
Drug: DDB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDB plus garlic oil (GO) - 2 capsules per day
Study: 22943930
Drug: DDB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDB plus garlic oil (GO) - 3 capsules per day
Study: 22943930
Drug: DDB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDB plus garlic oil (GO) - 6 capsules per day
Study: 22943930
Drug: DDB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDB plus garlic oil (GO) - all doses
Study: 15338257
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of Anti-oxLDL levels with anticardiolipin antibodies
Study: 15338257
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of Anti-oxLDL levels with beta(2)-glycoprotein I antibodies
Study: 11349744
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of ceftazidime 3 g/day
Study: 11349744
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of ceftazidime 2 g 3 times/day
Study: 11349744
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of ceftazidime
Study: 9625813
Drug: Induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy with modified CODBLAM IV regimen
Study: 9625813
Drug: Ara‐C at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ara‐C at low doses plus alphaIFN
Study: 9625813
Drug: alphaIFN as
Approvals — FDA: no, EMA: no, PMDA: no
Description: alphaIFN as maintenance therapy
Study: 7943077
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel (0.5 mg, two doses 6 hours apart)
Study: 7943077
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin (12 hours, up to 4 mlU/min)
Study: 31978882
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of preoperative hydrocortisone (group HC, n = 20)
Study: 31978882
Drug: Postoperative 3-month
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative 3-month pituitary hormone outcomes including ACTH deficiency
Study: 26830074
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy alone (32%) or in combination with other agents (17%)
Study: 23307105
Drug: Topical fluoroquinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical fluoroquinolone use at presentation
Study: 10821722
Drug: Bambuterol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bambuterol (10 mg or 20 mg tablets once daily)
Study: 10821722
Drug: Terbutaline (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (2.5 mg tablets three times daily)
Study: 10821722
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Bambuterol and Terbutaline)
Study: 8876850
Drug: Methyl salicylate
Normalized name: Methyl Salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl salicylate (12.5%) applied as an ointment, 5 g twice daily for 4 days (8 doses)
Study: 8876850
Drug: Trolamine salicylate
Normalized name: Trolamine Salicylate
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trolamine salicylate (10%) applied as a cream, 5 g twice daily for two doses
Study: 1545094
Drug: Oral challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenges to fish species
Study: 30304428
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B hemoperfusion plus standard therapy (n=224 patients)
Study: 30304428
Drug: Sham hemoperfusion
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham hemoperfusion plus standard therapy (n=226 patients)
Study: 30304428
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B hemoperfusion plus standard therapy (n=146 patients with MODS > 9)
Study: 30304428
Drug: Sham hemoperfusion
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham hemoperfusion plus standard therapy (n=148 patients with MODS > 9)
Study: 16215330
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy with specific adjuvant exercise
Study: 16215330
Drug: Sham manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham manual therapy with specific adjuvant exercise
Study: 2191977
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of autologous fibronectin with citric acid demineralisation
Study: 30784233
Drug: Integrated preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated preventive psychological intervention (IPPI) and N-acetyl-l-cysteine (NAC)
Study: 30784233
Drug: N-acetyl-l-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetyl-l-cysteine (NAC) and psychological stress management
Study: 23305133
Drug: Full-mouth disinfection
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth disinfection (FMD) group: full-mouth scaling and root planing (FMSRP) within 24 hours + local application of chlorhexidine (CHX) gel + CHX rinses for 60 days
Study: 23305133
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: full-mouth scaling and root planing (FMSRP) within 24 hours + local application of placebo gel + placebo rinses for 60 days
Study: 19702819
Drug: AmF-SnF2 mouth
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmF-SnF2 mouth rinse and toothpaste, used twice daily for 8 months
Study: 19702819
Drug: Placebo mouth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouth rinse and toothpaste, used twice daily for 8 months
Study: 16722802
Drug: Ketorolac 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.4% adjunctive regimen with cyclosporin-A
Study: 16722802
Drug: Cyclosporin-A monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin-A monotherapy
Study: 3770280
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion managed according to routine delivery unit practice (n = 36)
Study: 3770280
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion rates halved (n = 45)
Study: 3770280
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion rates quartered (n = 43)
Study: 3770280
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion discontinued (n = 40)
Study: 29145993
Drug: Synthetic bioabsorbable
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic bioabsorbable polymer spray
Study: 26801483
Drug: Immunoadsorption (IA)
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoadsorption (IA) therapy using tryptophan column
Study: 22513514
Drug: 3T optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3T optimized protocol (triple dose of Gd, 20 min scan delay)
Study: 22513514
Drug: 1.5T standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5T standard protocol (single dose of Gd, 5 min scan delay)
Study: 12051282
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% diclofenac (Group A)
Study: 12051282
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% dexamethasone (Group B)
Study: 7433477
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of methylglucamine indomethacinate (average dose 72.6 mg)
Study: 7433477
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of methylglucamine indomethacinate (average dose 36.1 mg)
Study: 22321682
Drug: Acellular tissue
Normalized name: ACELLULAR TISSUE ENGINEERED VESSEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular tissue matrix patch during Lichtenstein herniorrhaphy